These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 26237196)

  • 1. Baseline Predictors for Good Versus Poor Visual Outcomes in the Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Therapy.
    Chae B; Jung JJ; Mrejen S; Gallego-Pinazo R; Yannuzzi NA; Patel SN; Chen CY; Marsiglia M; Boddu S; Freund KB
    Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5040-7. PubMed ID: 26237196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy.
    Rush RB; Rush SW; Aragon AV; Ysasaga JE
    Am J Ophthalmol; 2014 Aug; 158(2):337-44. PubMed ID: 24844972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
    Peden MC; Suñer IJ; Hammer ME; Grizzard WS
    Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy.
    Bandello F; Corvi F; La Spina C; Benatti L; Querques L; Capuano V; Naysan J; Chen X; Sarraf D; Parodi MB; Souied E; Freund KB; Querques G
    Br J Ophthalmol; 2016 Dec; 100(12):1611-1616. PubMed ID: 26951773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Dolz-Marco R; Phasukkijwatana N; Sarraf D; Freund KB
    Retina; 2017 Feb; 37(2):222-233. PubMed ID: 27627752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes.
    Tao Y; Jonas JB
    Retina; 2010 Oct; 30(9):1426-31. PubMed ID: 20539255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
    Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
    Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE
    Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy.
    Engelbert M; Zweifel SA; Freund KB
    Retina; 2010 Oct; 30(9):1368-75. PubMed ID: 20517175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of intravitreal bevacizumab treatment between phakic and pseudophakic neovascular age-related macular degeneration.
    Ozkaya A; Alkin Z; Perente I; Yuksel K; Baz O; Alagoz C; Yazici AT; Demirok A
    Nepal J Ophthalmol; 2014; 6(2):145-52. PubMed ID: 25680245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Xu L; Mrejen S; Jung JJ; Gallego-Pinazo R; Thompson D; Marsiglia M; Freund KB
    Retina; 2015 Feb; 35(2):176-86. PubMed ID: 25387047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment.
    Fong KC; Kirkpatrick N; Mohamed Q; Johnston RL
    Clin Exp Ophthalmol; 2008 Nov; 36(8):748-55. PubMed ID: 19128380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries.
    Lad EM; Hammill BG; Qualls LG; Wang F; Cousins SW; Curtis LH
    Am J Ophthalmol; 2014 Sep; 158(3):537-43.e2. PubMed ID: 24857687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term effects of a single intravitreal bevacizumab injection on retinal vessel calibre.
    Tatlipinar S; Dinç UA; Yenerel NM; Görgün E
    Clin Exp Optom; 2012 Jan; 95(1):94-8. PubMed ID: 21954975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
    Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD
    Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation.
    Engelbert M; Zweifel SA; Freund KB
    Retina; 2009; 29(10):1424-31. PubMed ID: 19898180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optical Coherence Tomography Angiography of Type 1 Neovascularization in Age-Related Macular Degeneration.
    Kuehlewein L; Bansal M; Lenis TL; Iafe NA; Sadda SR; Bonini Filho MA; De Carlo TE; Waheed NK; Duker JS; Sarraf D
    Am J Ophthalmol; 2015 Oct; 160(4):739-48.e2. PubMed ID: 26164826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.